A multi-center, single-arm, open-label study to evaluate tolerability, safety, and efficacy of topical MOB015B solution in the treatment of mild to moderate distal subungual onychomycosis (DSO) in subjects aged 6-17 years

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513214-34-00

Enrollment

Registered

2024-07-25

Start date

2023-10-18

Completion date

Unknown

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distal Subungual Onychomycosis

Brief summary

Treatment success (defined as 0-10% clinical disease involvement of the target toenail and mycological cure of target toenail) at Week 48.

Interventions

DRUGTerclara

DRUGkutanopløsning

DRUGTerbinafina Moberg Pharma 98 mg/mL soluzione cutanea

DRUGTerbinafin "Moberg Pharma"

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Treatment success (defined as 0-10% clinical disease involvement of the target toenail and mycological cure of target toenail) at Week 48.	—

Countries

Denmark, Iceland, Italy, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026